With Teva continuing to report declining North American generics sales – albeit more than offset by increases in other territories and business units – the company has highlighted future targets in the US as it pushes forward with its new “pivot to growth” strategy.
With Teva’s second-quarter results presentation representing the first quarterly results since the firm launched its new “pivot to growth” strategy, it was no surprise that CEO Richard Francis began by talking up Teva’s branded interests.
He cited an “exciting quarter” for the firm thanks to the launch of its new once-a-day formulation of its deutetrabenazine...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
